Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research on AD presented at the American Academy of Dermatology 2017 Annual Meeting.


This activity has been designed for dermatologists, allergists, immunology specialists, internists, and primary care providers including physicians, nurse practitioners, physician assistants, and other healthcare professionals who are responsible for the diagnosis, treatment, or management of patients with atopic dermatitis (AD). No prerequisites required.



The goal of this activity is to provide up-to-date comprehensive information for clinicians on the treatment and management of patients with AD.


Upon completion of this activity, participants will be better able to do the following:

  1. Discuss current standards of care for AD management and treatment-related limitations.
  2. Describe newer findings in the pathogenesis of AD and the potential role of these pathways in treatment development.
  3. Integrate the latest information on new and emerging advancements from AAD 2017 into the treatment of patients with AD.


Lawrence Eichenfield, MD (Chair)
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology

University of California
San Diego School of Medicine
San Diego, California

Eric L.Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research

Oregon Health and Science University
Portland, Oregon

Emma Guttman, MD, PhD
Vice Chair of Research, Dermatology Department
Professor of Dermatology and Immunology
Director, Center for Excellence in Eczema
Director, Occupational/Contact Dermatitis Clinic
Director, Laboratory of Inflammatory Skin Diseases

Icahn School of Medicine
Mount Sinai Medical Center
New York, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Lawrence Eichenfield, MD (Chair)

Speakers’ Bureau: Valeant

Consultant/Advisor: Allergan; Anacor Pharmaceuticals, Inc.; Dignity Services Ltd.; Eli Lilly and Company; Galderma; Genentech, Inc.; Otsuka Pharmaceutical Co., Ltd/Medimetriks Pharmaceuticals Inc.; Pfizer Inc.; Ralexar Therapeutics; Regeneron Pharmaceuticals, Inc.; TopMD Inc; Valeant

Grant/Research Support: Regeneron Pharmaceuticals, Inc.

Eric L.Simpson, MD, MCR

Consultant/Advisor: Celgene Corporation; Dermira, Inc.; Galderma; Genentech, Inc; GlaxoSmithKline plc; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi

Grant/Research Support: GlaxoSmithKline plc; Novartis AG: Regeneron Pharmaceuticals, Inc.; Tioga Pharmaceuticals; Vanda Pharmaceuticals

Emma Guttman, MD, PhD

Consultant/Advisor: AbbVie Inc; Almirall S.A.; Anacor Pharmaceuticals, Inc.; Asana BioSciences, LLC; Celgene Corporation; Dermira, Inc.; Eli Lilly and Company; Eskalier; Galderma; Glenmark Pharmaceuticals Ltd.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma Inc.; MedImmune; Mitsubishi Tanabe Pharma Corporation; Novartis AG; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi; Stiefel Laboratories, Inc.; Vitae Pharmaceuticals, Inc.

Grant/Research Support: Celgene Corporation; Eli Lilly and Company; LEO Pharma Inc; MedImmune; Novartis AG; Regeneron Pharmaceuticals, Inc.

Non-faculty: Lou Settembrino; Ankita Patel, PharmD; Sandy Breslow; Leah Johnson; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.


CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, Sanofi Genzyme and Regeneron Pharmaceuticals Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.